PPD, Inc.: insider trades · United States · SEC (Form 4)

About PPD, Inc.

PPD, Inc. is a U.S.-based clinical research and pharmaceutical development services company, historically focused on supporting pharmaceutical, biotechnology, medical device, academic, and government clients across the drug development lifecycle. Founded in 1985 by Fred Eshelman as a small consulting practice, PPD evolved into a global contract research organization (CRO) with capabilities spanning clinical trial management, laboratory services, data management, regulatory support, and drug-development operations. In December 2021, Thermo Fisher Scientific completed its acquisition of PPD, making PPD a wholly owned subsidiary and integrating it into Thermo Fisher’s pharmaceutical services platform. That transaction marked the company’s most important recent corporate milestone and materially changed how investors should view the franchise today. Historically associated with Wilmington, North Carolina, PPD has also been tied to Thermo Fisher’s U.S. corporate footprint in Waltham, Massachusetts. For equity investors, it is important to note that PPD is no longer an independently listed public company; the relevant listed parent is Thermo Fisher Scientific, which trades on the NASDAQ in the United States. PPD’s core business lines include early- and late-stage clinical trial execution, site activation and enrollment solutions, central laboratory and analytical services, biometrics, medical monitoring, and real-world evidence / post-approval support. Its value proposition is built on global scale, scientific depth, therapeutic breadth, and the ability to run complex multinational trials for large biopharma customers. Competitive positioning is strong within the global CRO market, where the key differentiators are operational execution, regulatory expertise, geographic reach, and access to specialized patient and site networks. PPD operates internationally, with a broad presence across North America, Europe, and Asia-Pacific, enabling it to support global study designs and regionally localized execution. From a market standpoint, the company participates in a structurally attractive segment of healthcare outsourcing, where rising R&D complexity and cost pressure continue to support demand for third-party development services. Recent business context has therefore centered less on standalone corporate updates and more on integration within Thermo Fisher’s Life Sciences and Laboratory Products ecosystem, where PPD complements the group’s instruments, consumables, and lab services. For investors monitoring SEC Form 4 activity, PPD should be understood as a strategic healthcare-services asset embedded within a NASDAQ-listed U.S. parent rather than as an independent NYSE/NASDAQ issuer.